Literature DB >> 23278720

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.

Philippe Armand1, Sarah Welch, Haesook T Kim, Ann S LaCasce, Eric D Jacobsen, Matthew S Davids, Caron Jacobson, David C Fisher, Jennifer R Brown, Erin Coughlin, Arnold S Freedman, Yi-Bin Chen.   

Abstract

In the positron emission tomography (PET) era, traditional prognostic factors may not apply for patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) undergoing autologous stem cell transplantation (ASCT). Moreover, little is known about prognostic factors in patients transplanted for transformed indolent lymphoma (TIL). We conducted a retrospective study of 143 patients with R/R DLBCL and TIL who were transplanted in the last decade and had a post-salvage PET scan. We examined prognostic factors in both groups, and constructed a prognostic score for DLBCL patients. For patients with DLBCL, post-salvage PET response was an important prognostic factor. Advanced age and symptomatic relapse were also significantly associated with outcome. A simple score could stratify patients into three risk groups with 4-year post-ASCT overall survival of 84%, 59%, and 10%, and 4-year progression-free survival of 67%, 41% and 0% (P<0.0001 for both). However, none of those factors (including PET response to salvage) appeared relevant for patients with TIL, despite their comparable overall outcome. Our prognostic score for DLBCL patients undergoing ASCT may be useful for prognostication, for stratification in clinical trials, and to motivate the design of new strategies for patients in the high-risk group, who may not derive benefit from standard ASCT.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278720     DOI: 10.1111/bjh.12176

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

Review 1.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

2.  CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors:  Craig S Sauter; Brigitte Senechal; Isabelle Rivière; Ai Ni; Yvette Bernal; Xiuyan Wang; Terence Purdon; Malloury Hall; Ashvin N Singh; Victoria Z Szenes; Sarah Yoo; Ahmet Dogan; Yongzeng Wang; Craig H Moskowitz; Sergio Giralt; Matthew J Matasar; Miguel-Angel Perales; Kevin J Curran; Jae Park; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2019-07-01       Impact factor: 22.113

3.  Frequency and reasons for return to the primary acute care service among patients with lymphoma undergoing inpatient rehabilitation.

Authors:  Jack B Fu; Jay Lee; Dennis W Smith; Ki Shin; Ying Guo; Eduardo Bruera
Journal:  PM R       Date:  2013-12-31       Impact factor: 2.298

4.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Authors:  Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

5.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Authors:  Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

Review 6.  Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Victor A Chow; Mazyar Shadman; Ajay K Gopal
Journal:  Blood       Date:  2018-06-18       Impact factor: 22.113

7.  A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.

Authors:  Ho-Young Yhim; Yael Eshet; Ur Metser; Chae-Hong Lim; Katherine Lajkosz; Keren Isaev; Matthew Cooper; Anca Prica; Vishal Kukreti; Sita Bhella; Noémie Lang; Kyung-Han Lee; Wei Xu; David Hodgson; Richard Tsang; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim; Michael Crump; John Kuruvilla; Robert Kridel
Journal:  Blood Adv       Date:  2020-11-24

Review 8.  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Anupama Doraiswamy; Mansi R Shah; Rajat Bannerji
Journal:  Curr Hematol Malig Rep       Date:  2021-02-22       Impact factor: 3.952

9.  Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

Authors:  Nirav N Shah; Kwang W Ahn; Carlos Litovich; Yizeng He; Craig Sauter; Timothy S Fenske; Mehdi Hamadani
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

10.  Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Authors:  Mehdi Hamadani; Parameswaran N Hari; Ying Zhang; Jeanette Carreras; Görgün Akpek; Mahmoud D Aljurf; Ernesto Ayala; Veronika Bachanova; Andy I Chen; Yi-Bin Chen; Luciano J Costa; Timothy S Fenske; César O Freytes; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; David J Inwards; Rammurti T Kamble; Edward J Kanfer; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard Olsson; Nishitha M Reddy; David A Rizzieri; Bipin N Savani; Melhem Solh; Julie M Vose; Baldeep Wirk; David G Maloney; Sonali M Smith; Silvia Montoto; Wael Saber; Onder Alpdogan; Amanda Cashen; Christopher Dandoy; Robert Finke; Robert Gale; John Gibson; Jack W Hsu; Nalini Janakiraman; Mary J Laughlin; Michael Lill; Mitchell S Cairo; Reinhold Munker; Phil A Rowlings; Harry C Schouten; Thomas C Shea; Patrick J Stiff; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-05       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.